UNIVERSIDAD COMPLUTENSE DE MADRID FACULTAD DE FARMACIA UNA NUEVA
ESTRATEGIA BASADA EN EL DISEÑO DE FÁRMACOS MULTIDIANA PARA Page 1 …

La enfermedad de Alzheimer (EA) es la causa más común de demencia, probablemente el
60-70% de todas las demencias, y una de las enfermedades con mayor repercusión en los …

The cannabinoid (CB) system is widespread in the central nervous system and is crucial for
controlling a range of neurophysiological processes such as pain, appetite, and cognition …

Dementia refers to a group of neurocognitive disorders characterized by irreversible decline
in cognitive functions. It is invariably associated with severe disability, distress, and …

En estudios anteriores llevados a cabo en nuestro laboratorio hemos identificado ASS234,
como un compuesto-hit, multipotente, diseñado como un híbrido de donepezilo y PF9601N …

Given that neuronal degeneration in Alzheimer's disease (AD) is caused by the combination
of multiple neurotoxic insults, current directions in the research of novel therapies to treat this …

Alzheimer's disease (AD) is a neurodegenerative, irreversible disorder clinically
characterized by abnormal memory loss along with deterioration of other cognitive abilities …

In the present work, a bibliographic review of how cannabinoids can modulate the symptoms
and pathophysiology of Alzheimer's disease will be carried out. In the first place, the use of …

La enfermedad de Alzheimer es el tipo de demencia más común a nivel mundial, sin
embargo en la actualidad no existe ningún tratamiento curativo para la misma. La …

Alzheimer's disease (AD) is one of the most prevalent and debilitating neurodegenerative
diseases in the world, highlighting the need for research on novel treatments and therapies …